Common Stock, par value $0.001
- Symbol
- NXGL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 9.01 · 8-K
NexGel, Inc
NXGLNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description ────────────────────────────────────────────────────────────────────────── 99.1 Press release of NexGel, Inc. issued August 20, 2026. 104 Cover Page Interactive Data File (formatted as Inline XBRL)
Press release in this filing
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE →Recent company filings
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Other EventsNov 12, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 7, 2026
- Regulation FD DisclosureSep 24, 2026
- Submission of Matters to a Vote of Security HoldersSep 23, 2026
- DEF 14A filingAug 24, 2026
Registered securities in this filing
NEXGEL, INC. · 8-K · Filed 2026-08-21
Warrants to Purchase Common Stock
- Symbol
- NXGLW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No. Description
──────────────────────────────────────────────────────────────────────────
99.1 Press
release of NexGel, Inc. issued August 20, 2026.
104 Cover
Page Interactive Data File (formatted as Inline XBRL)
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE LANGHORNE, Pa. - August 20, 2026 - NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”) today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve liquidity, and enhance long-term shareholder value. The actions include the appointment of Brian Kieser as Interim Chief Executive Officer and the formation of a Special Committee for Strategic Review and Value Creation. Leadership Transition Effective August 21, 2026, Brian Kieser has been appointed Interim Chief Executive Officer of NEXGEL. Following the Company’s April 2026 acquisition of certain assets from Celularity, Inc., Mr. Kieser became actively involved in the integration of the BioNX Surgical division, manufacturing transition initiatives, commercialization strategy, financing activities, and broader strategic planning efforts through NEXGEL’s strategic partnership with Sequence Life Science, Inc. After careful consideration, the Board unanimously determined that Mr. Kieser is particularly well-positioned to lead the Company thr…
Open exhibit ↗